Ferroptosis-centered Drug Response Information
General Information of the Drug (ID: ferrodrug0373)
| Name |
XN4
|
||||
|---|---|---|---|---|---|
| Synonyms |
(5S)-5-butyl-4-({1-[(4-chlorophenyl)methyl]-1H-imidazol-5-yl}methyl)-1-[3-(trifluoromethoxy)phenyl]piperazin-2-one; CHEMBL5171383; XN4
Click to Show/Hide
|
||||
| Structure |
 |
||||
| Formula |
C26H28ClF3N4O2
|
||||
| IUPAC Name |
(5S)-5-butyl-4-[[3-[(4-chlorophenyl)methyl]imidazol-4-yl]methyl]-1-[3-(trifluoromethoxy)phenyl]piperazin-2-one
|
||||
| Canonical SMILES |
CCCCC1CN(C(=O)CN1CC2=CN=CN2CC3=CC=C(C=C3)Cl)C4=CC(=CC=C4)OC(F)(F)F
|
||||
| InChI |
InChI=1S/C26H28ClF3N4O2/c1-2-3-5-22-16-34(21-6-4-7-24(12-21)36-26(28,29)30)25(35)17-32(22)15-23-13-31-18-33(23)14-19-8-10-20(27)11-9-19/h4,6-13,18,22H,2-3,5,14-17H2,1H3/t22-/m0/s1
|
||||
| InChIKey |
POBHWQSJZMJUAH-QFIPXVFZSA-N
|
||||
| PubChem CID | |||||
Full List of Ferroptosis Target Related to This Drug
Prostaglandin G/H synthase 2 (PTGS2)
| In total 1 item(s) under this Target | ||||
| Experiment 1 Reporting the Ferroptosis-centered Drug Act on This Target | [1] | |||
| Target for Ferroptosis | Marker | |||
| Responsed Disease | Gastric cancer | ICD-11: 2B72 | ||
| Pathway Response | Fatty acid metabolism | hsa01212 | ||
| Ferroptosis | hsa04216 | |||
| Cell Process | Cell ferroptosis | |||
| In Vitro Model | SGC-7901 cells | Gastric carcinoma | Homo sapiens | CVCL_0520 |
| BGC-823 cells | Gastric carcinoma | Homo sapiens | CVCL_3360 | |
| GES-1 cells | Normal | Homo sapiens | CVCL_EQ22 | |
| Response regulation | The pro-ferroptotic role of XN4 in gastric cancer (GC) might enable it to become a promising drug for GC treatment in the future despite the need for extensive research. Moreover, GPX4 levels decreased, but NOX4 and ferroptosis-related protein PTGS2 levels increased in GC cells following XN4 treatment, which was nullified by NOX4 knockdown. | |||
Phospholipid hydroperoxide glutathione peroxidase (GPX4)
| In total 1 item(s) under this Target | ||||
| Experiment 1 Reporting the Ferroptosis-centered Drug Act on This Target | [1] | |||
| Target for Ferroptosis | Suppressor | |||
| Responsed Disease | Gastric cancer | ICD-11: 2B72 | ||
| Pathway Response | Fatty acid metabolism | hsa01212 | ||
| Ferroptosis | hsa04216 | |||
| Cell Process | Cell ferroptosis | |||
| In Vitro Model | SGC-7901 cells | Gastric carcinoma | Homo sapiens | CVCL_0520 |
| BGC-823 cells | Gastric carcinoma | Homo sapiens | CVCL_3360 | |
| GES-1 cells | Normal | Homo sapiens | CVCL_EQ22 | |
| Response regulation | The pro-ferroptotic role of XN4 in gastric cancer (GC) might enable it to become a promising drug for GC treatment in the future despite the need for extensive research. Moreover, GPX4 levels decreased, but NOX4 and ferroptosis-related protein PTGS2 levels increased in GC cells following XN4 treatment, which was nullified by NOX4 knockdown. | |||
NADPH oxidase 4 (NOX4)
| In total 1 item(s) under this Target | ||||
| Experiment 1 Reporting the Ferroptosis-centered Drug Act on This Target | [1] | |||
| Target for Ferroptosis | Driver | |||
| Responsed Disease | Gastric cancer | ICD-11: 2B72 | ||
| Pathway Response | Fatty acid metabolism | hsa01212 | ||
| Ferroptosis | hsa04216 | |||
| Cell Process | Cell ferroptosis | |||
| In Vitro Model | SGC-7901 cells | Gastric carcinoma | Homo sapiens | CVCL_0520 |
| BGC-823 cells | Gastric carcinoma | Homo sapiens | CVCL_3360 | |
| GES-1 cells | Normal | Homo sapiens | CVCL_EQ22 | |
| Response regulation | The pro-ferroptotic role of XN4 in gastric cancer (GC) might enable it to become a promising drug for GC treatment in the future despite the need for extensive research. Moreover, GPX4 levels decreased, but NOX4 and ferroptosis-related protein PTGS2 levels increased in GC cells following XN4 treatment, which was nullified by NOX4 knockdown. | |||